SELECT-1

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

SelumetinibOngoingActive not recruitingPhase 3Open NCT01933932 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…